Lurbinectedin is a chemotherapy drug that is used to treat certain types of cancer. According to Drug Patent Watch [1], the drug is still under patent protection, and it is not yet clear if it is effective in treating anemia during treatment. However, a study published in the Journal of Hematology & Oncology [3] suggests that anemia is a common side effect of lurbinectedin treatment.

The study examined the use of lurbinectedin in patients with advanced solid tumors, and found that anemia occurred in approximately 40% of patients. The study also found that the anemia was generally mild to moderate in severity, and that it could be managed with supportive care, such as blood transfusions or erythropoiesis-stimulating agents (ESAs).

Another study published in the same journal [2] examined the use of lurbinectedin in patients with small cell lung cancer, and found that anemia was also a common side effect of treatment. The study suggested that ESAs may be effective in managing anemia in these patients, but further research is needed to confirm these findings.

In conclusion, anemia is a common side effect of lurbinectedin treatment, but it can generally be managed with supportive care such as blood transfusions or ESAs. However, more research is needed to determine the most effective strategies for managing anemia in patients undergoing lurbinectedin treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6979357/
[3] https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0736-3